CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ombitasvir/ paritaprevir/ ritonavir

Last Updated: August 7, 2015
Result type: Reports
Project Number: SR0444-000
Product Line: Reimbursement Review

Generic Name: Ombitasvir/ paritaprevir/ ritonavir

Brand Name: Technivie

Manufacturer: AbbVie Corporation

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic (genotype 4)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 18, 2016

Recommendation Type: List with clinical criteria and/or conditions